Dr. Bhatnagar will also present a corporate overview at the
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, is currently being evaluated in a Phase III clinical development program.
For more information, please visit www.soleno.life.
LifeSci Advisors, LLC
Source: Soleno Therapeutics